ALK and non-small cell lung carcinoma: With promising results seen in individuals of advanced ALK-positive NSCLC, brigatinib underwent testing through the phase III trial called ALTA-1 L, which evaluated brigatinib and crizotinib in the first-line setting for patients with ALK-positive NSCLC (24).